Karin Hansson

Karin Marianne Hansson is the founder of Scandibio Therapeutics AB, founded in 2017, serving as Chief Executive Officer.
Dr. Hansson is the founder of Amylonix AB, founded in 2018, serving as Chief Executive Officer & Director.
Dr. Hansson is the founder of Scandiedge Therapeutics AB, founded in 2017, serving as Chief Executive Officer & Director.
Dr. Hansson is also the founder of Affibody AB,Protemedge AB,A05 Diagnostics AB..
Dr. Hansson is Chief Executive Officer & Director at Mariham Consulting AB. Dr. Hansson is Chief Executive Officer at Zytox Therapeutics AB. Former positions include Chief Executive Officer at Atlas Antibodies AB from 2006 to 2017, Independent Director at Q-linea AB from 2018 to 2023, Independent Director at Intervacc AB, Director at Atlas Therapeutics AB, Deputy Director at Antibodies Incentive AB, and Manager-Business Development at Affibody Medical AB. Education includes a graduate degree conferred in 1989 and a doctorate conferred in 1998, both from the Royal Institute of Technology.